CA-TRILINK-BIOTECH
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
“CleanCap® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink. “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430716807/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thunder Bridge Capital Partners IV, Inc. and Coincheck Group N.V. Announce Closing of Business Combination10.12.2024 23:52:00 CET | Press release
Coincheck Group N.V. ordinary shares and warrants to begin trading on Nasdaq on December 11, 2024 as “CNCK” and “CNCKW,” respectively. Coincheck Group N.V. (“Coincheck”), a Dutch public limited liability company and a holding company of a cryptocurrency trading service company, and Thunder Bridge Capital Partners IV, Inc. (Nasdaq: THCP, THCPU & THCPW) (“Thunder Bridge IV”), a special purpose acquisition company, announced today the consummation of their previously announced business combination. As a result, the ordinary shares and warrants of Coincheck will commence trading on Nasdaq on December 11, 2024 under the new ticker symbols “CNCK” and “CNCKW,” respectively. The business combination was approved at a special meeting of the shareholders of Thunder Bridge IV on December 5, 2024. “The completion of our business combination with Thunder Bridge IV marks an extraordinary milestone for Coincheck,” said Oki Matsumoto, Representative Executive Officer and Chairman of Monex Group, Inc.,
IFF Names Michael DeVeau Chief Financial Officer10.12.2024 22:15:00 CET | Press release
DeVeau has served in senior global financial leadership roles across the organization during his 15-year IFF tenure, most recently as SVP, Corporate Finance and Investor Relations IFF (NYSE: IFF) today announced that Michael DeVeau—currently Senior Vice President, Corporate Finance and Investor Relations at IFF—has been named the company’s Executive Vice President and Chief Financial Officer, effective Jan. 1, 2025. DeVeau will succeed current CFO and Business Transformation Officer Glenn Richter, whose previously announced planned retirement will take effect at the end of 2024. “We could not be more pleased than naming Mike as our CFO,” said Erik Fyrwald, IFF CEO. “Mike is a trusted, experienced executive at IFF and has been a pivotal leader across our company’s global finance functions over the last 15 years. We conducted a thorough evaluation process, and I am proud that we identified the right leader with decades of industry experience and longstanding relationships with the invest
Lattice Advances Low Power FPGA Leadership with New Small and Mid-range FPGA Offerings10.12.2024 19:00:00 CET | Press release
‒ Introduces Lattice Nexus 2 next-gen small FPGA platform, extends mid-range portfolio with Lattice Avant 30 and Avant 50 devices, and enhances capabilities of application-specific solution stacks and design software tools ‒ Today, at Lattice Developers Conference 2024, Lattice Semiconductor (NASDAQ: LSCC) expanded its edge to cloud FPGA innovation leadership with the launch of exciting new hardware and software solutions. The new Lattice Nexus™ 2 next-gen small FPGA platform and the first device family based on the platform, Lattice Certus™-N2 general purpose FPGAs, offer advanced connectivity, optimized power and performance, and class-leading security. Lattice also announced new mid-range FPGA device capacity options – Lattice Avant™ 30 and Avant™ 50 – and new versions of Lattice design software tools and application-specific solution stacks to help accelerate customer time-to-market. “At Lattice, we are proud to lead technological advancements in low power, small form factor FPGAs,
nShift: Growing Ecoms Urged to Stop “Leaving Money on the Table” in 202510.12.2024 17:01:00 CET | Press release
nShift releases five ways that deliveries can solve business problems Small and medium-sized ecommerce businesses fear they are leaving money on the table by failing to optimize their processes, learn from data analytics and improve their customer experience. Experts at nShift are calling on growing and ambitious ecom companies to make 2025 the year they start using the delivery process to maximize revenue and solve business challenges. Smaller ecommerce businesses are better placed than their larger competitors to respond quickly to shifting customer expectations. But many may be missing opportunities to spot these trends. One in five small businesses does not actively track ecommerce analytics.1 nShift, the global leader in delivery and experience management, has identified five ways that the delivery process can help grow revenue, boost loyalty and solve business problems: Increase conversions at checkout – some 70% of shoppers confess to abandoning online shopping carts.2 nShift da
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma10.12.2024 16:30:00 CET | Press release
The pivotal Phase 3 inMIND trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints in patients with relapsed or refractory follicular lymphoma (FL) treated with tafasitamab (Monjuvi®) in combination with lenalidomide and rituximabPositive data featured in a late-breaking oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for tafasitamab in FL by year-end 2024Incyte to host virtual analyst and investor event on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET to discuss key data presented at ASH Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom